ࡱ> :; l \pThe Free Software Foundation B=PF0*8X@"1 Helvetica1Courier1 Courier New1 Courier New1 Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)-**_($* #,##0_);_($* (#,##0);_($* "-"_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* "-"_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* "-"??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* "-"??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)6 0%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0)                + ) , *   Ј ~~ ؈ ~~#؈ ~~"؈ ~~ ؈ ~~8#܈ ~~83ffff̙̙3f3fff3f3f33333f33NO TITLEa November 3 2017November 3 2017 (1)$November 3 2017 (2)n5November 3 2017 (3)7GNovember 3 2017 (4)\2 3 4 5 Signature!hJOINT FILING AGREEMENT l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??November 3 2017November 3 2017 (1)November 3 2017 (2)November 3 2017 (3)November 3 2017 (4)2 3 4 5 SignatureJOINT FILING AGREEMENTU } $ } m)} $       Novartis Bioventures LtdSC 13G/A 11/07/2017NO TITLE UNITED STATES * "SECURITIES AND EXCHANGE COMMISSION   Washington, DC 20549      $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/&b@zn=[=PF0*8X> @ l  #  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? NO TITLENovember 3 2017 (1)November 3 2017 (2)November 3 2017 (3)November 3 2017 (4)2 3 4 5 SignatureJOINT FILING AGREEMENTU } $} m       Novartis Bioventures LtdSC 13G/A 11/07/2017November 3, 2017 o Rule 13d-1(b) x  Rule 13d-1(c) o  Rule 13d-1(d)  $ ____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$,~rf@=PF0*8X> @  l  6ts"  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? NO TITLENovember 3 2017November 3 2017 (2)November 3 2017 (3)November 3 2017 (4)2 3 4 5 SignatureJOINT FILING AGREEMENTU } $ } } $ }  6      Novartis Bioventures LtdSC 13G/A 11/07/2017November 3, 2017~ "Names of Reporting Persons  3 +I.R.S. Identification Nos. of Above Persons   (Entities Only)  ! NOVARTIS BIOVENTURES LTD.  ~  0 (Check the Appropriate Box if a Member ofa Group* (a) o (b) o~  SEC Use Only~ ,$Citizenship or Place of Organization SWITZERLAND Number of~ Sole Voting PowerShares~  BeneficiallyOwned by~ Shared Voting Power Each~ N# Reporting Person With~ Sole Dispositive Power~ Dl~rf&g[ ym;/R^ !"#$%&'()*+,-./012345   ~ " Shared Dispositive Power!!!!!~ !N#"#~ #&.#&Aggregate Amount Beneficially Owned by$$$Each Reporting Person%%~ %N#&'~ '*0'(Check Box if the Aggregate Amount in Row((%((9) Excludes Certain Shares o)*~ *..*&Percent of Class Represented by Amount+++in Row 9,, ,4.9%-.~ .2 .Type of Reporting Person// /CO00000012$3____________________________14)Created by Morningstar Document Research.05(http://documentresearch.morningstar.com/0`TObVj=PF0*8X> @*%554433//..,,++**((''%%$$##      l  6-3  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? NO TITLENovember 3 2017November 3 2017 (1)November 3 2017 (3)November 3 2017 (4)2 3 4 5 SignatureJOINT FILING AGREEMENTU } $ } } $ }  6      Novartis Bioventures LtdSC 13G/A 11/07/2017November 3, 2017~ "Names of Reporting Persons  3 +I.R.S. Identification Nos. of Above Persons   (Entities Only)    NOVARTIS AG  ~  0 (Check the Appropriate Box if a Member ofa Group* (a) o (b) o~  SEC Use Only~ ,$Citizenship or Place of Organization SWITZERLAND Number of~ Sole Voting PowerShares~  BeneficiallyOwned by~ Shared Voting Power Each~ N# Reporting Person With~ Sole Dispositive Power~ Dl~rf&ui{I=`(l% !"#$%&'()*+,-./012345   ~ " Shared Dispositive Power!!!!!~ !N#"#~ #&.#&Aggregate Amount Beneficially Owned by$$$Each Reporting Person%%~ %N#&'~ '*0'(Check Box if the Aggregate Amount in Row((%((9) Excludes Certain Shares o)*~ *..*&Percent of Class Represented by Amount+++in Row 9,, ,4.9%-.~ .2 .Type of Reporting Person// /CO00000012$3____________________________14)Created by Morningstar Document Research.05(http://documentresearch.morningstar.com/0`TObVj=PF0*8X> @*%554433//..,,++**((''%%$$##      l  ; ?F  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? NO TITLENovember 3 2017November 3 2017 (1)November 3 2017 (2)November 3 2017 (4)2 3 4 5 SignatureJOINT FILING AGREEMENTU } } 8 ;      Novartis Bioventures LtdSC 13G/A 11/07/2017November 3, 2017 Item 1(a).Name of Issuer: 0 (Akebia Therapeutics, Inc. (the ?Issuer?)  Item 1(b)./ 'Address of Issuer?s Principal Executive  Offices: / '245 First Street, Suite 1100, Cambridge   MA 02142, Item 2(a).Name of Person Filing:0(This statement is filed on behalf of the0(following persons with respect to shares&of common stock of the Issuer:.&(i) Novartis Bioventures Ltd., a Swiss0(corporation, with respect to shares held by it; and.&(ii) Novartis AG, a Swiss corporation,0(as the publicly owned parent of Novartis4,Bioventures Ltd., with respect to the shares( held by Novartis Bioventures Ltd-%The foregoing persons are hereinafter2*referred to collectively as the ?Reporting Persons.?Dl~rf5M, h2zb$hP !"#$%&'()*+,-./0123456789:  Item 2(b).0 (Address of Principal Business Office or,!!if none, Residence:"4",The address of the principal business office#1#)of Novartis Bioventures Ltd. and Novartis$7$/AG is Lichtstrasse 35, 4056 Basel, Switzerland.% Item 2(c).% Citizenship:&2&*Novartis Bioventures Ltd. is a corporation'/''organized under the laws of Switzerland(2(*and is an indirect wholly-owned subsidiary))of Novartis AG.**+.+&Novartis AG is a corporation organized,0,(under the laws of Switzerland and is the-5--publicly owned parent of Novartis Bioventures. .Ltd./ Item 2(d).%/Title of Class of Securities:020*Common Stock, par value $0.00001 per share11(the ?Common Stock?)2 Item 2(e).2 CUSIP Number:33 00972D 10545Item 3.5Not applicable.67$8____________________________19)Created by Morningstar Document Research.0:(http://documentresearch.morningstar.com/:MGOQq/xl`8=PF0*8X> @::9988 l  BQZX[  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? NO TITLENovember 3 2017November 3 2017 (1)November 3 2017 (2)November 3 2017 (3)2 3 4 5 SignatureJOINT FILING AGREEMENTU } I } } } y< B      Novartis Bioventures LtdSC 13G/A 11/07/2017November 3, 2017Item 4. Ownership.3 +Provide the following information regarding. &the aggregate number and percentage of8 0the class of securities of the Issuer identified  in Item 1.  (a)" Amount beneficially owned:0(Novartis Bioventures, Ltd. is the record1)owner of 2,312,403 shares of Common Stock0(of the Issuer. As the indirect parent of.&Novartis Bioventures, Ltd, Novartis AG/'may be deemed to beneficially own these securities. (b)Percent of class: 4.9% (c)0(Number of shares as to which such person has: (i)1)Sole power to vote or to direct the vote:Not applicable. (ii)3+Shared power to vote or to direct the vote:~ N# (iii):2Sole power to dispose or to direct the dispositionDl~rf=A\`8AsC !"#$%&'()*+,-./0123456789:;<=>?    of:!!!!Not applicable."" "(iv)0"(Shared power to dispose or to direct the####disposition of:$$$~ $N#%&Item 5.5&-Ownership of Five Percent or Less of a Class.2'*If this statement is being filed to report9(1the fact that as of the date hereof the reporting4),person has ceased to be the beneficial owner1*)of more than five percent of the class of*+"securities, check the following: x,-Item 6.5--Ownership of More than Five Percent on Behalf..of Another Person.//Not applicable.01Item 7.,1$Identification and Classification of222*the Subsidiary Which Acquired the Security3/3'Being Reported on By the Parent Holding44Company.55Not applicable.67Item 8.,7$Identification and Classification of88Members of the Group.99Not applicable.:;Item 9.';Notice of Dissolution of Group.<<Not applicable.=>$?____________________________D9l2i3[Oc!L{@A1@)Created by Morningstar Document Research.0A(http://documentresearch.morningstar.com/=PF0*8X> @2&AA@@??<<;;9988775544332211//..--++**))((''&&      l  %Qfg  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? NO TITLENovember 3 2017November 3 2017 (1)November 3 2017 (2)November 3 2017 (3)November 3 2017 (4)JOINT FILING AGREEMENTU } $ } } $ %      Novartis Bioventures LtdSC 13G/A 11/07/20172 3 4 5 Signature!NOVARTIS BIOVENTURES LTD.        By: /s/ Bartosz Dzikowski  Name: Bartosz Dzikowski  Title: Secretary of the Board By:/s/ Beat Steffen Name: Beat SteffenTitle:Authorized Signatory NOVARTIS AG By:/s/ Bartosz Dzikowski Name:Bartosz DzikowskiTitle:Authorized Signatory By:/s/ Giovanni Ferrara Name:Giovanni FerraraTitle:Authorized SignatoryDl}qe4v6D UZ !"#$ !$"____________________________1#)Created by Morningstar Document Research.0$(http://documentresearch.morningstar.com/ P=PF0*8X> @*$$##"" l  %qr  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? NO TITLENovember 3 2017November 3 2017 (1)November 3 2017 (2)November 3 2017 (3)November 3 2017 (4)2 3 4 5 SignatureU } $ } } $ %      Novartis Bioventures LtdSC 13G/A 11/07/2017JOINT FILING AGREEMENT!NOVARTIS BIOVENTURES LTD.        By: /s/ Bartosz Dzikowski  Name: Bartosz Dzikowski  Title: Secretary of the Board By:/s/ Beat Steffen Name: Beat SteffenTitle:Authorized Signatory NOVARTIS AG By:/s/ Bartosz Dzikowski Name:Bartosz DzikowskiTitle:Authorized Signatory By:/s/ Giovanni Ferrara Name:Giovanni FerraraTitle:Authorized SignatoryDlxl`/ q1 }?PU !"#$ !$"____________________________1#)Created by Morningstar Document Research.0$(http://documentresearch.morningstar.com/ P=PF0*8X> @*$$##"" Root Entry FBook  ms  !"#$%&'()*+,-./0123456789